Category: Novacyt Group

Paris, France and Camberley, UK – 23 April 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on the progress of its near-term COVID-19 research and development (R&D) programmes to address rapidly evolving testing demands, particularly as SARS-CoV-2 continues to mutate around the world. Novacyt also provides

Paris, France and Camberley, UK – 22 April 2021 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that following the announcement on 9 April 2021, the Company now intends to report its audited financial results for the year ended 31 December 2020 on 29 June 2021. http://novacyt.com/wp-content/uploads/2021/04/Novacyt-Notice-of-Results-22.04.21-ENGLISH.pdf

Paris, France and Camberley, UK – 9 April 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its supply contract with the UK Department of Health and Social Care (DHSC) and provides an unaudited trading update for the three months ended 31 March 2021. http://novacyt.com/wp-content/uploads/2021/04/Novacyt-trading-update-09.04.2021.pdf